Oncology

  • Hematologic complications after kidney and pancreas transplant in a patient with chronic myeloid leukemia
    Binoy Yohannan, MD, Allen Omo-Ogboi, MD, Johncy John Kachira, MBBS and Harinder Juneja, MD
    Cleveland Clinic Journal of Medicine March 2024, 91 (3) 183-190; DOI: https://doi.org/10.3949/ccjm.91a.23042

    This case highlights the complex interplay linking autoimmunity, solid-organ transplant, myeloid neoplasm, and Evans syndrome.

  • Management of venous thromboembolism in patients with active cancer
    CME article
    Heloni M. Dave, MBBS and Alok A. Khorana, MD, FACP, FASCO
    Cleveland Clinic Journal of Medicine February 2024, 91 (2) 109-117; DOI: https://doi.org/10.3949/ccjm.91a.23017

    The authors review the presentation and diagnosis of venous thromboembolism in patients with cancer and present an approach to treatment that aims to balance the bleeding risk from anticoagulation with the risk of recurrent thrombosis.

  • Gastric intestinal metaplasia and gastric cancer prevention: Watchful waiting
    Shrouq Khazaaleh, MD, Mohammad Alomari, MD, Mamoon Ur Rashid, MD, Daniel Castaneda, MD and Fernando J. Castro, MD
    Cleveland Clinic Journal of Medicine January 2024, 91 (1) 33-39; DOI: https://doi.org/10.3949/ccjm.91a.23015

    Malignancy develops in only a small minority of patients with gastric intestinal metaplasia. Recognition of clinical, endoscopic, and histologic features linked with cancer development is critical to identifying patients who require endoscopic surveillance.

  • Cutaneous metastasis from gastric carcinoma
    Li-wen Zhang, MD, Wen-ju Wang, MD, Tao Chen, MD, PhD and Rong-hua Xu, MD
    Cleveland Clinic Journal of Medicine September 2023, 90 (9) 533-534; DOI: https://doi.org/10.3949/ccjm.90a.22085

    The patient presented with asymptomatic nodules and alopecia of the scalp 3 years after treatment for gastric adenocarcinoma.

  • Unilateral green pleural effusion in a 22-year-old woman
    Sauradeep Sarkar, MD, Utsav Shrestha, MD, Huda Elzahrany, MD and Bathmapriya Balakrishnan, BMedSci, BMBS, FCCP
    Cleveland Clinic Journal of Medicine August 2023, 90 (8) 491-498; DOI: https://doi.org/10.3949/ccjm.90a.22097

    Chills, night sweats, palpitations, and a 5-lb weight loss, preceded by 6 months of progressive dyspnea, fatigue, and reduced exercise tolerance. What is the diagnosis?

  • Late complications after allogeneic hematopoietic cell transplant: What primary care physicians can do
    Lauren M. Granat, DO, MS, Mariah Ondeck, MD, Bennett Osantowski, MD, Michael Sheu, MD, Vishwanath Ganesan, MD, Seth Rotz, MD and Betty K. Hamilton, MD
    Cleveland Clinic Journal of Medicine August 2023, 90 (8) 499-508; DOI: https://doi.org/10.3949/ccjm.90a.23006

    Cardiovascular, metabolic, endocrine, rheumatologic, orthopedic, infectious, neurologic, and cognitive complications are examined, as well as secondary malignancies, psychiatric disorders, and impairments in quality of life and sexual health.

  • Atypical hyperplasia of the breast: Clinical cases and management strategies
    Suneela Vegunta, MD, Dawn M. Mussallem, DO, Aparna S. Kaur, MD, Sandhya Pruthi, MD and Christine L. Klassen, MD
    Cleveland Clinic Journal of Medicine July 2023, 90 (7) 423-431; DOI: https://doi.org/10.3949/ccjm.90a.22098

    The authors describe common clinical case scenarios for atypical hyperplasia of the breast and review management strategies for each scenario.

  • Surgical de-escalation: Are we ready for ‘observation’ of benign high-risk breast lesions found on core needle biopsy?
    Holly J. Pederson, MD, Debra Pratt, MD and Benjamin C. Calhoun, MD, PhD
    Cleveland Clinic Journal of Medicine July 2023, 90 (7) 433-438; DOI: https://doi.org/10.3949/ccjm.90a.23024

    Surgical de-escalation is part of a larger movement of de-escalation of multidisciplinary breast cancer treatment. The challenge is to balance oncologic outcomes with surgical morbidity and quality of life.

  • Endocrinopathies from checkpoint inhibitors: Incidence, outcomes, and management
    Endocrinopathies from checkpoint inhibitors: Incidence, outcomes, and management
    Randol Kennedy, MD, FACP, Hussein Awada, MD, Naga Vura, MD, Daniela Ciltea, MD and Michael Morocco, MD
    Cleveland Clinic Journal of Medicine May 2023, 90 (5) 307-317; DOI: https://doi.org/10.3949/ccjm.90a.22032

    A review of the incidence and severity of each immune checkpoint inhibitor-related endocrinopathy, factors related to toxicity risk, and principles of management.

  • Reincarnating autoimmunity: Immune-related adverse events as new diseases
    Pauline Funchain, MD
    Cleveland Clinic Journal of Medicine May 2023, 90 (5) 318-319; DOI: https://doi.org/10.3949/ccjm.90a.23013

    The range of adverse events is broad. Any organ can be affected, and any naturally occurring autoimmune process can be mimicked by the massive inflammation generated by checkpoint inhibition.

Pages